[go: up one dir, main page]

MX2007005367A - Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. - Google Patents

Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.

Info

Publication number
MX2007005367A
MX2007005367A MX2007005367A MX2007005367A MX2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A MX 2007005367 A MX2007005367 A MX 2007005367A
Authority
MX
Mexico
Prior art keywords
remodeling
ranolazine
treatment
heart failure
combination
Prior art date
Application number
MX2007005367A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MX2007005367A publication Critical patent/MX2007005367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a un metodo para revertir la remodelacion del ventriculo izquierdo mediante la administracion combinada de cantidades terapeuticamente efectivas de ranolazina y de por lo menos un agente de co-remodelacion, que puede ser un inhibidor de ACE, ARB, o un bloqueador-beta. El metodo encuentra utilidad en el tratamiento de la insuficiencia cardiaca. Esta invencion tambien se refiere a formulaciones farmaceuticas que son adecuadas para tal administracion combinada.
MX2007005367A 2004-11-09 2005-11-09 Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. MX2007005367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09
PCT/US2005/040824 WO2006053161A1 (en) 2004-11-09 2005-11-09 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Publications (1)

Publication Number Publication Date
MX2007005367A true MX2007005367A (es) 2007-06-18

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005367A MX2007005367A (es) 2004-11-09 2005-11-09 Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.

Country Status (15)

Country Link
US (2) US20060111361A1 (es)
EP (1) EP1809289A1 (es)
JP (1) JP2008519770A (es)
KR (1) KR20070084063A (es)
CN (1) CN101072562A (es)
AU (1) AU2005304421A1 (es)
BR (1) BRPI0517650A (es)
CA (1) CA2586840A1 (es)
IL (1) IL183056A0 (es)
MX (1) MX2007005367A (es)
NO (1) NO20072934L (es)
RU (1) RU2007121707A (es)
SG (1) SG156681A1 (es)
WO (1) WO2006053161A1 (es)
ZA (1) ZA200703697B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
JP5522663B2 (ja) * 2006-09-08 2014-06-18 カーディオポリマーズ， インコーポレイテッド 全体的な心臓のサイズ変更および再形成のための心筋内パターン形成
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
WO2008080012A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010523264A (ja) * 2007-04-11 2010-07-15 ヘンリー フォード ヘルス システム 心臓の静脈系を用いた心臓の修復、リサイジング、およびリシェイピング
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
JP6998942B2 (ja) * 2016-09-19 2022-01-18 アビオメド インコーポレイテッド 心機能を定量化し、心臓の回復を促進する心血管補助システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0719558T3 (da) * 1989-06-23 2002-10-07 Syntex Llc Ranolzin og beslægtede piperazin til anvendelse ved behandling af chocktilstande
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
NO20072934L (no) 2007-08-08
IL183056A0 (en) 2007-10-31
RU2007121707A (ru) 2008-12-20
EP1809289A1 (en) 2007-07-25
WO2006053161A8 (en) 2006-09-14
AU2005304421A1 (en) 2006-05-18
ZA200703697B (en) 2008-09-25
US20060111361A1 (en) 2006-05-25
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09
CN101072562A (zh) 2007-11-14
WO2006053161A1 (en) 2006-05-18
KR20070084063A (ko) 2007-08-24
CA2586840A1 (en) 2006-05-18
JP2008519770A (ja) 2008-06-12
BRPI0517650A (pt) 2008-10-14

Similar Documents

Publication Publication Date Title
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2004010937A3 (en) Method of treating cancer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20072654L (no) Cancer behandling
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
GB0018527D0 (en) Composition
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
HK1198869A1 (en) Combination treatments for hepatitis c
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2021003845A (es) Composiciones para reducir el acido urico serico.
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
BRPI0518700B8 (pt) combinação contendo vegf-trap, 5-fluorouracila e ácido folínico